Prof Jesus San Miguel presents data during press conference at the 18th EHA meeting in Stockholm.

Treatment for patients with multiple myeloma (MM) has improved over the last decade due to the introduction of new drugs such as lenalidomide and bortezomib.

However, after receiving multiple treatments, MM patients often become resistant (refractory) to these drugs and have an average survival of only 9 months.

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, pomalidomide (POM) in combination with low-dose dexamethasone (POM LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage disease which have previously failed lenalidomide and bortezomib.

Visit ecancerNews to read more